Celldex Therapeutics Inc.

NASDAQ: CLDX · Real-Time Price · USD
24.88
-0.06 (-0.24%)
At close: Aug 15, 2025, 10:01 AM

Celldex Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
7.02M 6.88M 2.36M 4.65M
Cost of Revenue
3.18M 3.01M 1.4M 3.07M
Gross Profit
7.02M -111.13M -79.9M 1.58M
Operating Income
-195.08M -154.54M -115.23M -71.24M
Interest Income
37.22M 13.11M 2.91M 505K
Pretax Income
-157.86M -141.43M -112.33M -70.74M
Net Income
-157.86M -141.43M -112.33M -70.51M
Selling & General & Admin
38.55M 30.91M 27.2M 20.49M
Research & Development
163.55M 118.01M 82.26M 50.24M
Other Expenses
n/a -105.51M -74.12M -48.15M
Operating Expenses
202.1M 43.41M 35.33M 22.58M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
202.1M 161.43M 117.59M 75.89M
Income Tax Expense
n/a n/a n/a -227K
Shares Outstanding (Basic)
64.39M 48.45M 46.89M 42.87M
Shares Outstanding (Diluted)
64.39M 48.45M 46.89M 42.87M
EPS (Basic)
-2.45 -2.92 -2.4 -1.64
EPS (Diluted)
-2.45 -2.92 -2.4 -1.64
EBITDA
-191.9M -139.03M -104.2M -66.08M
EBIT
-195.08M -142.04M -107.1M -69.15M
Depreciation & Amortization
3.18M 3.01M 2.9M 3.07M